Diabetic foot osteomyelitis—infection of the bone underlying a foot ulcer—is among the most consequential complications of diabetic foot disease. It develops in a substantial proportion of infected diabetic foot ulcers and is strongly associated with the risk of lower-extremity amputation. Because clinical signs of bone infection can be subtle and overlap with soft-tissue infection, accurate diagnosis and appropriately targeted treatment are central to limb preservation. A 2023 review in JAMA notes that diabetic foot ulcers precede roughly 80% of lower-extremity amputations in people with diabetes, underscoring why the presence of underlying bone infection changes the clinical stakes considerably (Armstrong et al., 2023).
Why Diabetic Foot Osteomyelitis Is Difficult to Diagnose
Diabetic foot osteomyelitis rarely presents with the classic signs of bone infection seen in other populations. Peripheral neuropathy can mask pain, and comorbid peripheral arterial disease can blunt the inflammatory response, so erythema, warmth, and swelling may be minimal even with established bone involvement (Matheson et al., 2021). Clinicians are therefore taught to maintain a high index of suspicion whenever an ulcer is large, deep, of long duration, or overlies a bony prominence. A simple bedside maneuver—probing the ulcer with a sterile metal instrument to determine whether bone is palpable—remains a useful screening step, though its predictive value varies with the pretest probability of infection (Lipsky et al., 2020, IWGDF 2019 update).
Diagnostic Tools: From Imaging to Bone Biopsy
Plain radiographs are typically the first imaging study obtained, but early osteomyelitis can be radiographically silent for two to three weeks after onset. When radiographs are inconclusive or greater anatomic detail is needed for surgical planning, magnetic resonance imaging is the most useful advanced imaging modality, offering higher sensitivity and specificity for detecting marrow changes consistent with infection (Matheson et al., 2021). The IWGDF/IDSA 2023 guidelines identify bone biopsy—evaluated by both culture and histopathology—as the reference standard for confirming the diagnosis and identifying the causative organism, since superficial wound swabs frequently reflect surface colonization rather than the pathogens actually present in bone (Senneville et al., 2023). Emerging evidence supports percutaneous bedside bone biopsy as a safe alternative to biopsy obtained during surgery in appropriately selected patients, potentially expanding access to definitive microbiological diagnosis (Senneville et al., 2023).
Antibiotic Therapy: Selection and Duration
Staphylococcus aureus and streptococcal species are the most frequently isolated organisms in diabetic foot infections, although polymicrobial involvement, including gram-negative and anaerobic organisms, is common, particularly in chronic or previously treated wounds (Pitocco et al., 2019). Empiric antibiotic selection is guided by infection severity, local resistance patterns, and prior antibiotic exposure, then narrowed once culture results are available. For confirmed osteomyelitis, treatment courses are considerably longer than for soft-tissue infection alone. Current guidance generally supports a total antibiotic duration of up to six weeks when the infected bone is not completely resected surgically, with several groups now exploring whether shorter courses are adequate when surgical debridement removes the majority of infected bone (Lipsky & Uçkay, 2021). Where feasible, oral antibiotic regimens with high bone bioavailability have increasingly replaced prolonged intravenous therapy, reflecting both antimicrobial stewardship principles and evidence that oral step-down therapy achieves comparable outcomes in appropriately selected patients (Lipsky & Uçkay, 2021).
Surgical Versus Conservative Management
Historically, major amputation was a common endpoint for diabetic foot osteomyelitis. Improvements in diagnostic precision and surgical technique have shifted practice toward “conservative” or bone-sparing surgery, in which only necrotic or infected bone is resected, preserving as much of the functional foot as possible, particularly for forefoot involvement (Lipsky & Uçkay, 2021). The decision between primarily medical (antibiotic-only) management and surgical debridement depends on factors including the extent of bone involvement, vascular status, the presence of soft-tissue loss requiring coverage, and the patient’s overall surgical candidacy. The IWGDF/IDSA 2023 guidelines emphasize that this decision should be individualized and made collaboratively among the surgical, medical, and infectious disease members of the care team (Senneville et al., 2023).
Clinical Summary
Diabetic foot osteomyelitis is a diagnosis that depends on integrating clinical suspicion, imaging, and, where possible, bone culture and histopathology, since clinical signs alone are unreliable in this population. Magnetic resonance imaging remains the preferred advanced imaging study when plain films are inconclusive, and bone biopsy provides the most definitive microbiological data. Antibiotic therapy should be culture-directed where feasible, with duration guided by whether infected bone has been surgically resected. Surgical management has trended toward bone-sparing approaches, reflecting advances in both diagnostic accuracy and operative technique. Ongoing research continues to refine optimal antibiotic duration and the comparative role of medical versus surgical management, and clinicians should expect continued evolution of these recommendations as new evidence emerges.
References
Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic Foot Ulcers: A Review. JAMA. 2023;330(1):62-75.
Senneville É, Albalawi Z, van Asten SA, et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). Diabetes Metab Res Rev. 2023;40(3):e3687.
Lipsky BA, Uçkay Î. Treating Diabetic Foot Osteomyelitis: A Practical State-of-the-Art Update. Medicina (Kaunas). 2021;57(4):339.
Matheson EM, Bragg SW, Blackwelder RS. Diabetes-Related Foot Infections: Diagnosis and Treatment. Am Fam Physician. 2021;104(4):386-394.
Lipsky BA, Senneville É, Abbas ZG, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(S1):e3280.
Pitocco D, Spanu T, Di Leo M, et al. Diabetic foot infections: a comprehensive overview. Eur Rev Med Pharmacol Sci. 2019;23(2 Suppl):26-37.
Comments
